Investment funds managed by global private investment firm KKR will acquire Immedica Pharma, a Swedish pharmaceutical company focused on the commercialisation of medicines for rare diseases and specialty care products.
Nordic healthcare investment firm Impilo, the company’s existing owner, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
According to a press release, KKR and Impilo will work together with Immedica’s management team to support Immedica’s continued growth, including the launch of the recently approved ultra-orphan drug Loargys, additional pipeline assets, and continued in-licensing and M&A. The company is also evaluating an expansion into the US ahead of the regulatory filing and potential approval of Loargys by the US FDA.
Immedica Pharma was established in 2018 by Impilo and a management team with previous experience in launching and commercialising orphan drugs across Europe. The business has developed drugs primarily within haematology and oncology as well as genetic and metabolic diseases for rare conditions with high unmet medical need, with revenues of €100m and annual growth of more than 50%, according to the press release.
KKR is investing in Immedica through its KKR Health Care Strategic Growth Fund II, a $4bn fund focused on high-growth healthcare companies. KKR has invested approximately $20bn in the healthcare sector since 2004.
